Trial Profile
Epirubicin followed by Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) vs Epirubicin and Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (ET-CMF) as adjuvant chemotherapy in node positive patients with operable breast cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary) ; Paclitaxel (Primary) ; Cyclophosphamide; Fluorouracil; Methotrexate
- Indications Early breast cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results (n=557) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 01 Apr 2012 5-year results published in Breast Cancer Research and Treatment.
- 10 Dec 2009 New trial record